Adverse Cutaneous Reactions Following COVID-19 Vaccination Among Patients with Pre-Existing Urticaria: A Cross-Sectional Study at a Tertiary Care Center in Saudi Arabia
Notice bibliographique
Résumé
Ashwag Asiri,1 Hend M Alotaibi,2 Nouf Ali Alotaibi,3 Alfahdah Abdullah Alsaleem4 1Department of Child Health, College of Medicine, King Khalid University, Abha, Saudi Arabia; 2Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3Department of Family Medicine, King Fahad Medical City, Riyadh, Saudi Arabia; 4Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi ArabiaCorrespondence: Ashwag Asiri, Department of Child Health, College of Medicine, King Khalid University, P.O. Box 62527, Abha, Saudi Arabia, Email asalasiri@kku.edu.saPurpose: To investigate the incidence, characteristics, and associated factors of cutaneous adverse reactions to COVID-19 vaccines among adult patients with pre-existing urticaria in Saudi Arabia.Patients and Methods: A cross-sectional study enrolled 190 adult patients (≥ 18 years) with urticaria attending allergy/dermatology clinics at King Khalid University Hospital, Riyadh (November 2021–April 2022). Data on demographics, urticaria characteristics, vaccination status, cutaneous reactions, and comorbidities were collected via questionnaire. Statistical analyses included descriptive statistics, Chi-square/Fisher exact tests, Cochran’s test, and binary logistic regression.Results: Participants were predominantly female (87.4%), with chronic spontaneous urticaria (97.9%); 78.9% used regular antihistamines. Reactions occurred after dose 1 (22.7%), dose 2 (26.2%), and dose 3 (31.0%). Among symptomatic individuals, onset was typically < 24h, resolving in 1– 3 days for ~50%. Common reactions included injection site reactions (13.1– 16.3%), pruritus (7.8– 10.5%), and urticaria exacerbation (3.9– 9.1%). Urticaria exacerbation decreased significantly after dose 3 (p=0.030). Regular antihistamine use was associated with fewer reactions after dose 1 (adjusted OR 0.4, p=0.028). Female gender, asthma/atopy, and autoimmune disease were associated with specific reactions. Adjusted vaccine type showed no significant association.Conclusion: Cutaneous reactions post-COVID-19 vaccination in urticaria patients are relatively common but generally mild and transient. Decreasing urticaria exacerbations after dose 3 is reassuring. Regular antihistamine use may offer some protection, particularly after the first dose. Findings support vaccine safety and aid patient counseling.Plain Language Summary: Understanding how COVID-19 vaccines affect people with existing skin allergies is 41 crucial for public health. Our study focused on patients with urticaria (chronic hives) 42 who received COVID-19 vaccines. We found that while many patients experienced 43 mild skin reactions after vaccination, these reactions were generally temporary and 44 manageable. Most reactions occurred within 24 hours of vaccination and resolved within 45 a few days. Importantly, patients who regularly took antihistamine medications were 46 less likely to develop reactions. This research provides reassurance that COVID-19 47 vaccines can be safely administered to people with pre-existing urticaria, although some 48 may experience temporary symptoms. These findings help both healthcare providers 49 and patients make informed decisions about vaccination.Keywords: COVID-19, vaccine, urticaria, cutaneous adverse reaction, antihistamine, Saudi Arabia, cross-sectional study
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».